A Phase III trial of a potential new treatment for ovarian cancer, farletuzumab, did not know any improvement in progression free survival.
See a new article here
Ovarian Cancer National Alliance • 901 E Street NW, Suite 405 • Washington, DC 20004
(202) 331-1332 • toll-free: 1-866-399-6262 • fax: (202) 331-2292 • email@example.com
All content © Copyright 2014 by Ovarian Cancer National Alliance.
Subscribe to our RSS Feed or view our Sitemap
This site made possible by a grant from Novartis Oncology